BridgeBio Pharma Reports Strong Q2 Revenue Growth Amid Pending FDA Approvals

Key Facts

1BridgeBio reported Q2 2026 net revenues of $243.7M, significantly up from $110.6M in the prior year.

2Three New Drug Applications (NDAs) for BBP-418, oral infigratinib, and encaleret are currently under Priority Review by the FDA.

BridgeBio Pharma reported net revenues of $243.7 million in the second quarter of 2026, up significantly from $110.6 million in the prior year. Seeking Alpha reported that three New Drug Applications (NDAs) for BBP-418, oral infigratinib, and encaleret are currently under Priority Review by the U.S. Food and Drug Administration (FDA).

BBIO closed at $65.75 on October 12, 2026, with the stock trading between a day low of $65.2 and a high of $66.42 during that session. The company's financial performance and clinical pipeline progress support a positive outlook for 2026-2027, bolstered by encaleret data and late-stage development catalysts.